Hepion Pharmaceuticals enters $24M ATM equity offering with Cantor Fitzgerald

Hepion Pharmaceuticals, Inc.

ATM sales agreement with Cantor Fitzgerald allows Hepion to sell up to $24M of common stock at market prices.
Commission of 3.0% of gross proceeds paid to Cantor; Company provides customary indemnification.
Shares sold under existing effective shelf registration statement (File No. 333-254996).
No obligation to sell; offering terminates upon full issuance or termination of agreement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Hepion Pharmaceuticals, Inc. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at up to $24,000,000 (effective 2023-07-21).

Action: entry
Agreement: atm program
Counterparty: Cantor Fitzgerald & Co.
Value: up to $24,000,000
Effective: 2023-07-21

Exact text from the filing

On July 21, 2023, Hepion Pharmaceuticals, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. as sales agent (the “Agent”), pursuant to which the Company may offer and sell, from time to time through the Agent, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $24,000,000 (the “Shares”).

View on SEC.gov

281 material agreements filed in the last 30 days. Browse all material agreements →

Hepion Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-083084

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.